Literature DB >> 7643616

Detection of 11q23/MLL rearrangements in infant leukemias with fluorescence in situ hybridization and molecular analysis.

J A Martinez-Climent1, M J Thirman, R Espinosa, M M Le Beau, J D Rowley.   

Abstract

Cytogenetic abnormalities of band 11q23 have been found in more than 50% of infant leukemias regardless of the phenotype. Using probes for the MLL gene at 11q23, MLL rearrangements have been identified in 70-80% of all infant leukemias including virtually all of the cases with 11q23 translocations, as well as cases with apparently normal karyotypes. We reviewed the chromosomal pattern of 26 cases of infant leukemias (12 ALL, 12 AML, two AUL). Eleven had 11q23 translocations, five had other abnormalities, and 10 had a normal karyotype. To determine whether 11q23/MLL rearrangements were present in the leukemia cells of patients with a normal karyotype, we performed FISH and molecular studies of eight of these patients who had adequate material. Three were found to have 11q23/MLL abnormalities, two of them detected by FISH; one ALL case had a t(11;19) (q23;p13.3), and one AML case had a t(11;19) (q23;p13.1). Retrospective review confirmed the presence of the t(11;19) in a small percentage of poor quality metaphase cells in both cases. A rearrangement of the MLL gene was detected by Southern blot analysis of leukemic cells from a third patient with ALL; one cell with a deletion of 11q23 was found on karyotypic review. Therefore, in our series the actual incidence of 11q23 abnormalities in infant leukemias was 54% (14/26): 67% in ALL (8/12) and 50% in AML (6/12). Our findings suggest that most infant leukemias with apparently normal karyotypes that have a molecular rearrangement of the MLL gene are undetected subtle translocations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7643616

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

Review 1.  Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.

Authors:  Kelly Faulk; Lia Gore; Todd Cooper
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

2.  Panhandle PCR for cDNA: a rapid method for isolation of MLL fusion transcripts involving unknown partner genes.

Authors:  M D Megonigal; E F Rappaport; R B Wilson; D H Jones; J A Whitlock; J A Ortega; D J Slater; P C Nowell; C A Felix
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 3.  Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.

Authors:  Soheil Meshinchi; Franklin O Smith; Robert J Arceci
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

4.  Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study.

Authors:  Hayato Tamai; Hiroki Yamaguchi; Hiroyuki Hamaguchi; Fumiharu Yagasaki; Masami Bessho; Takeshi Kobayashi; Hideki Akiyama; Hisashi Sakamaki; Satoshi Takahashi; Arinobu Tojo; Ken Ohmine; Keiya Ozawa; Hirokazu Okumura; Shinji Nakao; Ayako Arai; Osamu Miura; Shigeo Toyota; Seiji Gomi; Yoshiro Murai; Noriko Usui; Keisuke Miyazawa; Kazuma Ohyashiki; Naoto Takahashi; Kenichi Sawada; Atsushi Kato; Kazuo Oshimi; Koiti Inokuchi; Kazuo Dan
Journal:  Int J Hematol       Date:  2008-02-06       Impact factor: 2.490

5.  Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group.

Authors:  Eva A Coenen; C Michel Zwaan; Dirk Reinhardt; Christine J Harrison; Oskar A Haas; Valerie de Haas; Vladimir Mihál; Barbara De Moerloose; Marta Jeison; Jeffrey E Rubnitz; Daisuke Tomizawa; Donna Johnston; Todd A Alonzo; Henrik Hasle; Anne Auvrignon; Michael Dworzak; Andrea Pession; Vincent H J van der Velden; John Swansbury; Kit-fai Wong; Kiminori Terui; Sureyya Savasan; Mark Winstanley; Goda Vaitkeviciene; Martin Zimmermann; Rob Pieters; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2013-08-23       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.